TRIB2 and ovarian carcinoma: Our results are in line with previous studies, reporting TRIB2 upregulation in response to survival factor withdrawal in primary T-cells and erythroleukaemia cells43, miR155 induction in acute myeloid leukaemia cells44 and cisplatin treatment in ovarian cancer cells6, which all associated with activation of the apoptotic pathway.